A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus
A study for patients with Lupus using study drug ustekinumab
Sponsor: Janssen Research & Development, LLC
Enrolling: Male and Female Patients
IRB Number: AAAQ7406
U.S. Govt. ID: NCT02349061
Contact: Anca Askanase: 212-305-0856 / ada20@cumc.columbia.edu
Additional Study Information: If you have active Systemic Lupus Erythematosus, also known as SLE or Lupus, you may be interested to learn about a clinical research study that is being conducted to study the safety and effectiveness of an investigational medication called ustekinumab for active Lupus. Eligible study participants will be provided with study medication and study-related medical care at no cost during the study.
This study is closed
Investigator
Anca Askanase, MD, MPH
Do You Qualify?
Have you been diagnosed with Lupus? Yes No
Have you had Lupus symptoms for at least 3 months? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Anca Askanase
ada20@cumc.columbia.edu
212-305-0856
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE